RespireRx Pharmaceuticals Inc (RSPI)

[sav79]

The puzzle pieces are falling into place.

From page 14 of the presentation:

3. Joint development agreement with Noramco Inc./Purisys, a leading dronabinol manufacturer, in which Noramco will provide in-kind funding for all API supplies prior to NDA approval in exchange for an exclusive purchase agreement and limited participation in the success of the product.

Two key takeaways from red highlighted portion:

- the CEO’s relationship with Noramco and consequently reason he is now CEO should be obvious.
- from recent news release: Mr. Dickason is a highly experienced senior executive with a proven and outstanding track record in the pharmaceutical industry. A seasoned pharmaceutical development professional with over 30 years of experience and 9 approved NDAs

Both the CEO and Dickason were key additions and evidence of the progression of drug developments.

4. In discussions with several firms for the development of a proprietary dronabinol formulation covered by our existing patents, providing market exclusivity until at least 2031

5. Clinical plan developed with Clinilabs Drug Development Corporation, a full-service CRO, which will oversee a Phase 3 trial. The draft clinical protocol, budget and timeline have been completed.

6. Clinical advisory panel composed of the major Key Opinion Leaders in OSA


This has huge potential for a run that mirrors some of the biggest moves we’ve seen in #potstock land.